X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MNPR-201 (camsirubicin) is a novel proprietary analog of widely used cancer drug doxorubicin. Doxorubicin is used to treat adult and pediatric solid and hematologic cancers including breast, gastric, ovarian and bladder cancer, soft tissue sarcomas, leukemias and lymphomas.
Lead Product(s): Camsirubicin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: MNPR-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Doxorubicin is used to treat adult and pediatric solid and hematologic cancers including breast, gastric, ovarian and bladder cancer, soft tissue sarcomas, leukemias and lymphomas.
Lead Product(s): Camsirubicin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: MNPR-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
Camsirubicin is a novel, proprietary analog of the widely used cancer drug doxorubicin. The current Phase 1b trial is designed to test camsirubicin at progressively higher doses than previously administered while using concomitant prophylactic G-CSF to prevent neutropenia.
Lead Product(s): Camsirubicin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: MNPR-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Camsirubicin is a novel, proprietary analog of the widely used cancer drug doxorubicin. The current Phase 1b trial is designed to test camsirubicin at progressively higher doses than previously administered while using concomitant prophylactic G-CSF to prevent neutropenia.
Lead Product(s): Camsirubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Doxorubicin is used to treat adult and pediatric solid and hematologic (blood) cancers including breast, gastric, ovarian and bladder cancer, soft tissue sarcomas, leukemias and lymphomas.
Lead Product(s): Camsirubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
Company announced the positive recommendation from safety review committee to escalate to the second dose level in its camsirubicin Phase 1b trial in patients with ASTS the decision was made following a review of safety data from the patients.
Lead Product(s): Camsirubicin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2021
Details:
The trial is evaluating the safety and anti-tumor activity of increasing doses of camsirubicin, an analog of doxorubicin, used in combination with growth factor support (pegfilgrastim/G-CSF) for the treatment of advanced soft tissue sarcoma (ASTS).
Lead Product(s): Camsirubicin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: Camsirubicin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
The company looks forward to initiating its previously announced Phase 2 clinical trial in ASTS in collaboration with its partner, Grupo Español de Investigación en Sarcomas, in 2020.
Lead Product(s): Camsirubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
